既往抗凝的房颤相关缺血性卒中患者复发卒中风险更高
本研究汇总韩国15个卒中中心与日本18个卒中中心共5645例非瓣膜性房颤相关急性缺血性卒中或短暂性脑缺血发作患者数据,其中1129例(20.0%)有既往抗凝史。随访至索引事件后1年,既往抗凝组复发缺血性卒中累积发生率为5.3%,无既往抗凝组为2.9%,多变量Cox共享脆弱模型显示既往抗凝与复发缺血性卒中风险更高相关(HR 1.50,95%CI 1.02-2.21),两组出血性卒中与全因死亡风险无显著差异。
要点
- 既往抗凝的NVAF相关卒中患者复发缺血性卒中风险更高(HR 1.50,95%CI 1.02-2.21)。
- 既往抗凝组复发缺血性卒中累积发生率为5.3%,无既往抗凝组为2.9%。
- 两组出血性卒中与全因死亡风险无显著差异。
核心结论
- NVAF相关卒中患者中,有既往抗凝史者复发缺血性卒中风险可能高于无既往抗凝史者。
研究设计与样本
- 研究汇总2011至2014年韩国卒中临床研究协作组(15个韩国卒中中心)与日本NVAF卒中急性管理注册研究(18个日本卒中中心)的个体患者数据。
- 韩国注册研究4841例合格患者与日本注册研究全部1192例患者汇总,全队列6033例,最终分析5645例。
主要发现
- 1129例(20.0%)有既往抗凝史,中位年龄75岁(四分位距69-81岁),女性2649例(46.9%)。
- 随访4617患者年(中位随访365天,四分位距335-365天)。
- 既往抗凝组复发缺血性卒中累积发生率为5.3%(60/1129),无既往抗凝组为2.9%(130/4516)。
- 多变量Cox共享脆弱模型显示既往抗凝组复发缺血性卒中风险更高(HR 1.50,95%CI 1.02-2.21)。
- 两组出血性卒中与全因死亡风险无显著差异。
临床怎么用
- 对NVAF相关缺血性卒中患者,应关注既往抗凝史并据此评估复发卒中风险。
- 既往抗凝后仍发生卒中的NVAF患者可能需要进一步查找抗凝失败原因并优化二级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Ischemic stroke associated with nonvalvular atrial fibrillation (NVAF) despite prior anticoagulation may indicate underlying problems that nullify the stroke-preventing effects of oral anticoagulants. We aimed to evaluate the risk for recurrent stroke in patients with NVAF with prior anticoagulation, compared with that in patients without prior anticoagulation. Methods- This study comprised pooled individual patient data on NVAF-associated acute ischemic stroke or transient ischemic attack from 2011 to 2014 arising from the Clinical Research Collaboration for Stroke in Korea (15 South Korean stroke centers) and the Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-NVAF registry (18 Japanese stroke centers). Data on 4841 eligible patients from the Clinical Research Collaboration for Stroke in Korea registry were pooled with data on all patients (n=1192) in the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-NVAF registry. The primary outcome was recurrent ischemic stroke. The secondary outcomes were hemorrhagic stroke and all-cause death. Outcome events were captured up to 1 year after the index event. Results- Among the 6033 patients in the full cohort, 5645 patients were analyzed, of whom 1129 patients (20.0%) had received prior anticoagulation. Median age was 75 years (interquartile range, 69-81 years), and 2649 patients (46.9%) were women. Follow-up data of 4617 patient-years (median follow-up 365 days, interquartile range 335-365 days) were available. The cumulative incidence of recurrent ischemic stroke in patients with prior anticoagulation was 5.3% (60/1129), compared with the 2.9% (130/4516) incidence in patients without prior anticoagulation. The risk for recurrent ischemic stroke was higher in patients with prior anticoagulation than in those without (multivariable Cox shared-frailty model, hazard ratio 1.50 [95% CI, 1.02-2.21]). No significant differences in the risks for hemorrhagic stroke and mortality were seen between the 2 groups. Conclusions- The risk for recurrent ischemic stroke may be higher in NVAF-associated stroke patients with prior anticoagulation than in those without prior anticoagulation. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01581502.
引用
- Tanaka K, Koga M, Lee KJ, et al. Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke. Stroke. 2020. PMID: 32098607. doi:10.1161/STROKEAHA.119.027275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。